Equities Analysts Issue Forecasts for JBIO FY2026 Earnings

Jade Biosciences, Inc. (NASDAQ:JBIO – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Jade Biosciences in a note issued to investors on Monday, November 16th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($2.25) per share for the year, up from their previous estimate of ($2.41). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Jade Biosciences’ current full-year earnings is ($2.51) per share. HC Wainwright also issued estimates for Jade Biosciences’ Q4 2026 earnings at ($0.53) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($2.32) EPS, FY2029 earnings at ($2.37) EPS and FY2030 earnings at ($1.85) EPS.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.31.

Several other research firms have also recently weighed in on JBIO. Wall Street Zen upgraded Jade Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 14th. BTIG Research reiterated a “buy” rating on shares of Jade Biosciences in a research note on Monday. Wedbush reiterated an “outperform” rating and issued a $47.00 price target on shares of Jade Biosciences in a research note on Thursday, October 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Finally, Guggenheim lowered their price target on Jade Biosciences from $47.00 to $41.00 and set a “buy” rating for the company in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Jade Biosciences has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Check Out Our Latest Report on Jade Biosciences

Jade Biosciences Price Performance

Shares of NASDAQ:JBIO opened at $15.06 on Wednesday. Jade Biosciences has a 1 year low of $11.02 and a 1 year high of $28.00. The company’s 50 day simple moving average is $15.00 and its 200 day simple moving average is $18.13.

Hedge Funds Weigh In On Jade Biosciences

Several large investors have recently bought and sold shares of JBIO. Bank of New York Mellon Corp bought a new position in Jade Biosciences in the 2nd quarter valued at approximately $1,896,000. Janus Henderson Group PLC acquired a new stake in Jade Biosciences during the 1st quarter worth approximately $43,557,000. Renaissance Technologies LLC boosted its position in Jade Biosciences by 94.0% during the 1st quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock worth $1,897,000 after buying an additional 65,438 shares during the period. Stempoint Capital LP acquired a new stake in Jade Biosciences during the 1st quarter worth approximately $2,164,000. Finally, Maven Securities LTD bought a new stake in Jade Biosciences during the 2nd quarter worth approximately $1,111,000.

Latest Jade Biosciences News

These are some of the JBIO news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.25 per share from a loss of $2.41, while maintaining its Buy rating and $55 price target.
  • Negative Sentiment: HC Wainwright trimmed estimates for several upcoming quarters and fiscal years, including FY2027–FY2030, signaling expectations of somewhat larger losses than previously forecast.
  • Negative Sentiment: A separate report’s headline describes Guggenheim’s outlook for JBIO as pessimistic; the provided article details do not specify its forecast or price target. Guggenheim Issues Pessimistic Forecast for Jade Biosciences (NASDAQ:JBIO) Stock Price

Jade Biosciences Company Profile

(Get Free Report)

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.

Featured Articles

Earnings History and Estimates for Jade Biosciences (NASDAQ:JBIO)

Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.